Abstract. MicroRNAs (miRs) are small non-coding RNA molecules that regulate gene expression at the post-transcriptional level. Aberrant expression of miR-9 has been reported to be involved in the tumorigenesis and progression of various malignancies. However, its role in prostate cancer (PC) has not been completely clarified. In the present study, miR-9 expression was examined in different PC cell lines, patient tissues and a mouse model. Cell Counting Kit-8 and BrdU immunofluorescence assays were performed to assess the effect of miR-9 on the viability of PC cells, while Transwell and wound-healing assays were utilized to evaluate the migration and invasion of PC cells expressing miR-9. Furthermore, a dual-luciferase reporter assay was performed to verify whether mitogen-activated protein kinase kinase kinase 3 (MEKK3) was a direct target of miR-9. The results demonstrated significant downregulation of miR-9 expression in different PC cell lines and 31 human PC tissues, as compared with that in a normal prostate cell line and adjacent normal tissues, respectively. By contrast, upregulation of MEKK3 was confirmed in human PC tissue samples, with its level inversely associated with miR-9 expression. Overexpression of miR-9 in six different PC cell lines (DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP) reduced the cell viability and migration. Furthermore, it was demonstrated that the 3'-untranslated region of MEKK3 was a target of miR-9, and that MEKK3 overexpression prevented the inhibitory effects of miR-9 on the viability, migration and invasion of PC cells. miR-9 overexpressing tumor cells also exhibited growth delay in comparison with control tumor cells in vivo. Taken together, the current study findings provided novel insights into the underlying molecular mechanisms of PC oncogenesis, which may support the development of new therapeutic approaches for the treatment of PC.

Introduction

Prostate cancer (PC) is among the top 10 cancer types worldwide in terms of its high rates of prevalence and mortality. Recent research has indicated that the estimated mortalities associated with PC are higher in comparison with any other cancer type, excluding lung carcinoma (1). PC is typically treated with a combination of prostatectomy, radiation, chemotherapeutics and androgen ablation (2). However, the occurrence of distant invasion and migration of PC result in poor prognosis (3). At present, there is increasing research regarding PC invasion and migration, which are the major malignant properties of PC and main causes of mortality in patients (4-6).

MicroRNAs (miRs) are a class of small non-coding RNAs (7). The update of the miRBase in 2011, a biological database of miR sequences, currently includes >30,000 known mature miR sequences described in 9 species (8). It is well established that ectopic miR expression is strongly associated with tumorigenesis. miRs may be oncogenic or tumor suppressors, and have been widely reported as potential targets for cancer molecular therapies (9). Furthermore, miRs may be used as biomarkers or therapeutic targets for the diagnosis and prognosis of multiple types of cancer. Studies on PC invasion and metastasis have revealed a pivotal role of miRs during these processes, as miRs post-transcriptionally regulate a variety of invasion or metastasis-associated oncogenes (10,11).

The functional implication of miR-9 in evolution is demonstrated by its conservation at the nucleotide level in several different species, and it is known that the mature miR-9 sequence is identical in insects and humans (12). miR-9 has been extensively investigated in various biological processes, including neural progenitor cell proliferation and migration (13), neuronal differentiation (14), apoptotic cell death (15), brain function, neurodegeneration (16) and cancer (17). Aberrant miR-9 expression occurs in several types of cancer, suggesting that miR-9 is involved in tumorigenesis and cancer progression. However, through regulation of various mRNA targets, miR-9 may have divergent effects on the proliferation of various cancer cells (18-21). Although numerous functions of miR-9 have been reported, the mechanisms underlying its oncogenic or tumor suppressor functions have yet to be fully revealed.
As a major signaling pathway participating in signal transduction from the plasma to the nucleus, mitogen-activated protein kinases (MAPKs) respond to cellular stressors and various growth factors to mediate signaling (22). Mitogen-activated protein kinase kinase kinase 3 (MEKK3), also known as MAP3K, belongs to the MAPK family. MEKK3 is a kinase that phosphorylates the serine or threonine of c-Jun N-terminal kinase (JNK), p38 and extracellular signal-regulated kinase (ERK). MEKK3 is an upstream mediator of MAPK pathways regulating cell proliferation, tumorigenesis, apoptosis and inflammatory responses (23). Recently, the ability of MEKK3 to promote the transformation of breast epithelial cells has been revealed, suggesting that it functions as an oncogene (24). However, while MEKK3 is essential for endothelial function, it is not critical for tumorigenesis and angiogenesis (25). Currently, the role of MEKK3 in PC development and its underlying molecular mechanism in tumorigenesis remain unclear.

The aim of the present study was to investigate the effect of miR-9 on PC development. It was demonstrated that alteration of miR-9 expression in different PC cells influenced their proliferation and migration in vitro and in vivo. In addition, alterations in E-cadherin, N-cadherin and Vimentin expression levels were detected at the protein and mRNA level, confirming the effect of miR-9 on the epithelial-mesenchymal transition (EMT) of PC cells. It was also confirmed that miR-9 influenced PC cell behavior via targeting of the MEKK3 3′-untranslated region (3′-UTR). The present study expanded the current understanding on the role of miR-9 as a PC suppressor, and may facilitate the future development of miR-targeted cancer diagnostics and therapeutics.

Materials and methods

Cell lines and cell culture. Several cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). These included human normal prostate RWPE-1 cells, as well as DU145, LNCaP and PC-3 cells, which are standard PC cell lines used in therapeutic research (26). 22Rv1 was also obtained, which is a human prostate carcinoma epithelial cell line derived from a xenograft that was serially propagated in mice following castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft (27). C4-2B cells, a subtype of the LNCaP cell line, and VCaP cells, an adherent epithelial cell line with high androgen receptor and prostate-specific antigen expression, were also obtained (28,29). VCaP cell line is the only PC cell model that expresses the androgen receptor splice variant, AR-V7, with TMPRSS2-ERG gene fusion. Several cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). These included human normal prostate RWPE-1 cells, as well as DU145, LNCaP and PC-3 cells, which are standard PC cell lines used in therapeutic research (26). 22Rv1 was also obtained, which is a human prostate carcinoma epithelial cell line derived from a xenograft that was serially propagated in mice following castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft (27). C4-2B cells, a subtype of the LNCaP cell line, and VCaP cells, an adherent epithelial cell line with high androgen receptor and prostate-specific antigen expression, were also obtained (28,29). VCaP cell line is the only PC cell model that expresses the androgen receptor splice variant, AR-V7, with TMPRSS2-ERG gene fusion.

RWPE-1 cells were cultured in 1X defined keratinocyte serum-free medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). LNCaP, 22Rv1, C4-2B and PC-3 cells were grown in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.), while DU145 and VCaP cells were grown in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS. All cells were incubated at 37°C in a humidified atmosphere with 5% CO2 and routinely subcultured using 0.25% (w/v) trypsin-ethylenediaminetetraacetic acid solution.

Patients. PC patients (diagnosed with National Institute for Health and Clinical Excellence (NICE) criteria, n=31) (30) aged between 26 and 70 years, with a mean age of 53 years, were recruited into the present study. Clinicopathological information for these patients was obtained from medical records. The corresponding PC paraneoplastic tissues and their normal adjacent tissues were acquired at ≥1 cm from the neoplastic tissue. All cases were initially treated by prostatectomy and randomly selected at Qilu Hospital of Shandong University (Jinan, China) between March 2011 and April 2016. Specimens were obtained in agreement with the Declaration of Helsinki and were preserved at Qilu Hospital. The experimental protocol was approved by the Ethical Committee of Qilu Hospital of Shandong University (Jinan, China). Written informed consent for sample use in this research was obtained from both patients and clinicians. All samples were reviewed and diagnosed by two independent pathologists.

miR-9 expression vector construction. A versatile expression vector of miR-9 was generated by constructing the human miR-9 precursor region into minicircle vectors. A transthyretin (TTR) gene promoter was inserted upstream of the miR-9 precursor to guarantee liver-specific expression of miR-9 (31). This construct was referred to as TTR-miR-9. To exclude non-specific effects of the plasmid, a miR-9 mismatched expression vector was generated by mutating the seed region of miR-9, termed transthyretin-miR-9-mut.

miR-9 mimic preparation and transfection. miR-9 mimic and its scramble control [negative control (NC) mimic] were purchased from GenScript (Piscataway, NJ, USA). miR-9 mimic is an artificial chemically-modified double-strand miRNA, which mimics mature endogenous miR-9 expression subsequent to transfection into cells. Transfection of miRNA mimic was carried out by using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. All miRNA treatments proceeded for 48 h. Both miR-9 mimic and miR-NC mimic were formulated in 0.9 % NaCl to a final concentration of 10 mg/ml.

For enforced expression of MEKK3 in PC cells, open reading frame region of MEKK3 gene was amplified and inserted into the pcDNA3.1 eukaryotic expression vector (Invitrogen; Thermo Fisher Scientific, Inc.). Vector empty pcDNA3.1 was served as negative control (NC). Before transfection, cells were seeded into 6-well plates overnight. 3 µg/ml pcDNA3.1-MEKK3 or pcDNA3.1 plasmid was then transfected into the PC cells by using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

In vivo tumorigenesis in a PC mouse model. To detect whether upregulation of miR-9 reduced the tumorigenic capacity of PC cells, an intratibial injection model was established. A total of 6 male severe combined immunodeficiency mice at 3–4 weeks old were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Mice were kept at 23°C in a humidified atmosphere (55-65% humidity) with food and water ad libitum with a 12-h light/dark cycle. In order to establish the PC animal model, each mouse was injected with 1x105 stably selected PC-3 cells into its right tibia, while
with PC-3 cells transfected with NC vector cells were injected into the left tibia, serving as the NC group. Tumor length and width were measured every 3 days after injection, and tumor volume was calculated as follows: Length x (width^2)/2. Mice were sacrificed at 33 days after the injection, and the tumors were weighed. Ethical approval of the animal experiments was provided by the Institutional Animal Care and Use Committee of Shandong University Cancer Center (Jinan, China; approval no. L102012016110D).

Cell Counting Kit-8 (CCK-8) assay. PC cell viability was determined by a CCK-8/WST-8 assay (Dojindo Molecular Technologies, Inc., Shanghai, China), which was performed following a standard procedure in a 96-well plate, according to the manufacturer's protocol. Briefly, cells (5x10^3 cells/well) were seeded in a 96-well plate and grown to 80% confluence. miR-9 mimic or mimic NC was subsequently transfected into PC cells. At 0, 24, 48 and 72 h post-transfection, 10 µl of CCK-8 reagent was added into each well. After 1 h of incubation, cell viability was determined by measuring the absorbance of the converted dye at 450 nm.

BrdU immunofluorescence assay. DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells (1-5x10^5) were seeded on glass coverslips placed in a 6-well plate. Following transfection with miR-9 mimic and miR-NC for 48 h, 10 mg/ml BrdU stock solution in phosphate buffered saline (PBS) was diluted to 1,000X in the culture medium and incubated for 60 min. Cells were washed with PBS, fixed for 20 min at 25˚C in 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 for 10 min. Subsequent to blocking with 10% FBS for 1 h, cells were incubated with a primary rabbit antibody against BrdU (1:200; cat. no. ab6326, Abcam, Cambridge, UK) overnight at 4˚C and then incubated with the corresponding secondary antibody coupled to a fluorescent marker, Cy3 (A10520, Thermo Fisher Scientific, Inc.), at room temperature for 2 h. Following DAPI staining for 15 min at 37˚C and a further wash with PBS, the cover slips were mounted onto glass slides and visualized using a fluorescence microscope (Olympus 600 auto-biochemical analyzer; Olympus Corporation, Tokyo, Japan) with Image-Pro Plus software (Media Cybernetics, Inc., Rockville, MD, USA) for image analysis. A total of 10 microscopic fields were analyzed to calculate the degree of BrdU staining.

Transwell assays. After 24 h of transfection, DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells were harvested by trypsinization and washed once with D-Hank's solution. In order to measure cell invasion, 8-µm pore size culture inserts or m pore size culture inserts or 1~5x10^5 cells/well/well were seeded in a 96-well plate and grown to 80% confluence. miR-9 mimic or mimic NC was subsequently transfected into PC cells. At 0, 24, 48 and 72 h post-transfection, 10 µl of CCK-8 reagent was added into each well. After 1 h of incubation, cell viability was determined by measuring the absorbance of the converted dye at 450 nm.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from PC cells following different treatments or from homogenized PC tissues (stored at -80˚C) using TRIzol® reagent (Thermo Fisher Scientific, Inc.), according to manufacturer's protocol. The RNA (10 mg) was reverse transcribed into first-strand complementary DNA (cDNA) using M-MLV reverse transcriptase (Promega Corporation, Madison, WI, USA) for mRNA expression analysis. The levels of miR-9 were determined by SYBR Green incorporation in a Roche Light-Cycler 480 Real-time PCR system (Roche Diagnostics GmbH, Mannheim, Germany). GAPDH and U6 served as an internal control to determine the miR-9, E-cadherin, N-cadherin, Vimentin and MEKK3 expression. The primer sequences used in qPCR were as follows: miR-9, 5'-TGAAGGTAGTAAGTTGTATGTT-3' (forward) and 5'-ACACATTTCTTACATTCCTGATT-3' (reverse); E-cadherin, 5'-GGTTGTGTCTCAAGGACTTGG-3' (forward) and 5'-CACCAACACCCAGCAGCATATG-3' (reverse); N-cadherin, 5'-CGAGGCGCTGCGCTGCCAC-3' (forward) and 5'-CCGCTGCTCCCGC-3' (reverse); Vimentin, 5'-AGATCGATGGGACGTTCCTC-3' (forward) and 5'-CACCTGTCTCCG-3' (reverse).
miR-9 expression is reduced in PC cells and tissues. To identify whether miR-9 is an essential regulator in PC progression and development, miR-9 expression was examined in a PC mouse model, human PC tissues and six different PC cell lines, including the brain metastatic PC cell line DU145, the lymph node metastatic cell line LNCaP, the primary PC cell line 22Rv1, and the bone metastatic PC cell lines PC-3, C4-2B and VCaP. Initially, miR-9 expression was examined in normal prostate cells (RWPE-1) (35,36) and the six PC cell lines. RT-qPCR analysis revealed that miR-9 expression was significantly reduced in the six PC cell lines compared with that in the normal cell line (Fig. 1A). In addition, the expression levels of miR-9 were evaluated in 31 human PC prostatic tissues and 16 adjacent normal tissues. The results revealed that miR-9 expression was significantly lower in human prostatic tissues in comparison with that in normal tissues (Fig. 1B). Furthermore, the expression of miR-9 was measured in normal mouse prostatic tissues and prostatic tumor collected from a PC mouse model. It was observed that miR-9 expression was markedly reduced in prostate tumors of the mouse model, as compared with that in the normal group (Fig. 1C). Taken together, these data demonstrated that PC cells and tissues exhibited a marked decrease in miR-9 expression, compared with that observed in normal cells or tissues, respectively.

Effect of miR-9 on PC cell viability. To assess the role of miR-9 on the growth and viability of PC cells, miR-9-mimic or miR-NC were transfected into DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells. The expression pattern of miR-9 was confirmed to be upregulated in these six PC cell lines following transfection with miR-9-mimic, as compared with cells transfected with miR-NC and untransfected cells, by RT-qPCR assay (Fig. 2A). A CCK-8 assay was also performed to assess the proliferation of the six cell lines. Compared with the miR-NC group, transfection with miR-9-mimic at a
Figure 2. Effect of miR-9 overexpression on PC cell viability. (A) Quantitative polymerase chain reaction was used to measure the expression of miR-9 in each PC cell line transfected with miR-9 mimic and miR-NC mimic. (B) Viability of PC cell lines, as measured by Cell Counting Kit-8 assay at 0, 24, 48 and 72 h post transfection. (C) At 48 h post transfection, the viability of PC cell lines was determined by a BrdU incorporation assay. Data represent the mean ± standard deviation. *P<0.05, **P<0.01 and ***P<0.001, vs. normal group. miR, microRNA; PC, prostate cancer; NC, negative control; OD, optical density.
concentration of 100 nM resulted in a decreased cell growth rate in the six PC cell lines at 0, 24, 48 and 72 h after transfection (Fig. 2B). Furthermore, BrdU immunofluorescence assay was performed to measure the cell viability at 48 h after transfection with miR-9-mimic. The BrdU staining results revealed that, compared with miR-NC and untransfected groups, miR-9-mimic transfection inhibited viability in DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells by approximately 30, 50, 40, 50, 40 and 30%, respectively; however, the change in DU145 cells was not statistically significant (Fig. 2C). Overall, these results revealed that miR-9 overexpression displayed an inhibitory effect on cell viability in a time-dependent manner in these six PC cell lines.

miR-9 inhibits PC cell migration and invasion. Research has demonstrated that the invasion and migration of PC cells is major cause for mortality during PC development and metastasis into the bone. To determine whether miR-9 expression impacted the invasion and migration of PC cells, wound-healing and Transwell migration were conducted following the transfection of DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells with miR-9 and miR-NC mimics. The Transwell assay demonstrated that ectopic miR-9 expression had a significant inhibitory effect on invasion of these cells (Fig. 3A), which was consistent with the migration data obtained from the wound-healing assay (Fig. 3B). The wound-healing assay was also performed to detect the migratory capacity of DU145, 22Rv1, and LNCaP cells, and the results revealed that miR-9 overexpression caused marked suppression of these three PC cells migration, particularly in 22Rv1 cells (Fig. 3B). The results suggested that miR-9 overexpression suppressed the migratory and invasive properties of PC cells in vitro.

Effect of miR-9 on EMT. Epithelial-mesenchymal transition (EMT) serves an essential role in tumor invasion and migration.
Figure 4. E-cadherin, N-cadherin and Vimentin expression correlates with miR-9 transfection. (A) Western blot analysis of E-cadherin, N-cadherin and Vimentin protein levels in PC cells transfected with miR-9 mimic or miR-NC. (B) E-cadherin, (C) N-cadherin and (D) Vimentin mRNA levels were examined by quantitative polymerase chain reaction in PC cell lines. Representative data from three independent experiments are presented as the mean ± standard deviation. *P<0.05 and **P<0.01, vs. NC group. miR, microRNA; PC, prostate cancer; NC, negative control.
Western blotting and RT-qPCR were performed to reveal the effect of miR-9 on EMT, through examining the protein and gene expression levels of epithelial marker E-cadherin, mesenchymal marker N-cadherin and Vimentin. E-cadherin protein expression in each PC cell line of the miR-9 mimic-transfected group was markedly upregulated, compared with that in the NC group. By contrast, N-cadherin and Vimentin expression levels were notably decreased by miR-9 overexpression when compared with those in the NC group (Fig. 4A). In addition, E-cadherin, N-cadherin and Vimentin mRNA expression levels in the miR-9 mimic-transfected groups were significantly changed, compared with those in the NC group, in the majority of cell lines (P<0.05). More specifically, E-cadherin mRNA was significantly increased, whereas N-cadherin and Vimentin mRNA levels were markedly reduced in the miR-9 groups (Fig. 4B-D).

**MEKK3 is a target of miR-9.** MEKK3, which has been well-documented as a mediator of development and migration of other cancers (37-39), was identified as a functional candidate target for miR-9 by bioinformatics analysis (Fig. 5A). MEKK3 expression was thus examined in PC cells transfected with miR-9 mimic or miR-NC mimic by western blot analysis and RT-qPCR. MEKK3 expression was markedly suppressed in the miR-9 mimic-transfected group at the protein and mRNA levels (Fig. 5B and C). A dual-luciferase reporter assay, which is widely applied to confirm the binding of miRs to the promoter region of genes (40-42), was also performed in PC cell lines to determine if there was a direct interaction between MEKK3 and miR-9. The data demonstrated that miR-9 mimic transfection decreased luciferase activity, which was fused with the MEKK3 3'-UTR, as compared with in the control group (Fig. 5D).
Overexpression of MEKK3 protein suppresses the inhibitory effect of miR-9 on PC cell viability and migration. To further determine whether the inhibitory effect of miR-9 on PC development was exerted through targeting MEKK3, the expression of MEKK3 was restored in six PC cell lines (DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells) expressing miR-9. By performing a BrdU immunofluorescence assay, it was identified that increased expression of MEKK3 inhibited the miR-9-mediated viability decrease of DU145, LNCaP, 22Rv1, PC-3, C4-2B and VCaP cells (Fig. 6A). Transwell migration assays for DU145 and LNCaP cells, which have showed best invasive capacity in above mentioned experiments, were performed to further assess the effect of MEKK3 overexpression on these PC cells that were overexpressing
miR-9. As expected, the MEKK3 + miR-9-overexpressing cells displayed enhanced invasive capacity, compared with in the group transfected with miR-9 mimic alone (Fig. 6B). MEKK3 overexpression also inhibited the miR-9-induced E-cadherin upregulation and N-cadherin downregulation (Fig. 6C). Taken together, the data indicated that increased MEKK3 expression reduced the miR-induced inhibition of PC cell growth and invasion. The data also strongly suggested that the inhibitory effect observed in PC cells by miR-9 overexpression was exerted through cross-talk between miR-9 and MEKK3.

miR-9 inhibits prostate tumor growth in vivo. To further demonstrate the effect of miR-9 on PC development in vivo, a mouse model was established through intratibial injection. The mice were sacrificed, and tumors were excised and weighed at 30 days after injection. As presented in Fig. 7A, upregulation of miR-9 inhibited the xenograft prostate tumor development ability in vivo. In addition, mice injected with PC cells that were transfected with miR-9 mimics exhibited a marked reduction in tumor volumes compared with those inoculated with control PC cells (Fig. 7B). Furthermore, overexpression of miR-9 greatly reduced the weight of tumors (Fig. 7C). These observations indicated that the upregulation of miR-9 repressed prostate tumor formation.

Discussion

Tumor development is a complex synergistic process, involving the activation of oncogenic and suppression of tumor suppressor signaling networks, which may be associated with epigenetic alterations. Although PC has been extensively investigated in previous studies, the underlying mechanisms of PC remain poorly understood due to its complexity. In the present study, a specific miRNA was identified, namely miR-9, which was downregulated in six different PC cell lines (DU145, LNCaP, 22Rv1, PC-3, C4-2B, and VCaP). In addition, it was observed that overexpression of miR-9 in these cell lines inhibited cell viability and migration. In vivo experiments demonstrated that the inoculation of PC-3 cells expressing miR-9 into an immune-deficient mouse model resulted in a robust inhibitory effect on prostate tumor growth. The ability of miR-9 to inhibit the expression of MEKK3, a key diagnostic and therapeutic target of PC, was also identified. Further investigation demonstrated that miR-9 directly bound to the 3'-UTR of MEKK3 and abrogated its expression. Restoration of MEKK3 expression prevented the inhibitory effects of miR-9 in PC cells. The findings of the present study strongly suggested that miR-9 suppressed PC development via the regulation of cell viability through MEKK3 regulation, and provided evidence for the use of this miRNA as a potential target in PC therapy.

Accumulating studies have focused on the effects of miRNAs in PC therapy, due to their stability and relatively high uptake by the prostate (43). The identified inhibitory effect of miR-9 on PC was not unpredictable, since its role as an oncogene or tumor suppressor, depending on the cancer type, has been previously established. Several studies have demonstrated that miR-9 is upregulated in breast cancer, brain cancer, and melanoma (17,44,45). By contrast, a number of other studies have indicated that miR-9 is downregulated in certain types of cancer, including cervical adenocarcinoma, and hepatocellular, ovarian and gastric carcinoma (20,46-49), suggesting a bidirectional role of miR-9 in cancer. Accordingly, miR-9 may have different gene targets depending on the tumor type. In the current study, miR-9 expression in PC cell lines and tumor tissues obtained from 31 PC patients was significantly downregulated compared with that in normal cells and tissues. However, restoration of miR-9 expression in PC cells inhibited the cell viability in vitro and tumor development in vivo. Furthermore, the data demonstrated that miR-9 expression was inversely associated with MEKK3 expression in PC cell lines.

MEKK3, a member of the MEKK family, is ubiquitously expressed in various human tissues; however, increased MEKK3 expression in cancer indicates a high risk of tumor progression and is correlated with poor prognosis. MEKK is an upstream regulator of the MAPK cascade and activates multiple MAPKs, including ERK1/2, p38, JNK, ERK5 and nuclear factor (NF)-κB (50). The role of MAPKs in tumorigenesis has been extensively investigated over the last decade, particularly in the cases of ERK1/2 and NF-κB (51). Recently, the focus of research has shifted to the potential role of MEKKs in tumor development and progression. For instance, MEKK3 has been reported to contribute to the development of cervical (37), breast (24) and esophageal cancer (32). It also
has the ability to induce tumor cell migration and invasion via MAPK pathway activation. In the present study, MEKK3 was identified to be a direct target of miR-9. Previously, it has been proven that positive results in dual-luciferase reporter assay, combined with the identification of the miR-downregulated target protein, are sufficient to verify the interaction between miR and the gene of the target protein (40–42). This provides evidence for the function of miR-9 in the regulation of PC cell proliferation, migration, invasion and EMT, at least partially through targeting the 3′-UTR of MEKK3.

EMT is the transformation process of epithelial cells into mesenchymal cells. It has also been demonstrated to be involved in tumor development and progression, particularly in tumor metastasis (52). In the present study, MEKK3 overexpression markedly reduced the inhibitory effect of miR-9 transfection on PC viability, invasion and EMT marker expression. The present data demonstrated that miR-9 may suppress the neoplastic capacity of PC cells.

In conclusion, the data presented in the current study suggested that miR-9 exerted a multifunctional anti-tumor effect against the major malignant properties of PC cell lines. In addition, it was revealed that miR-9 reduced tumor development in a PC mouse model. These effects were demonstrated to be, at least partially, mediated by MEKK3 regulation. Nevertheless, it cannot be excluded that miR-9 may target other factors and thus contribute to PC pathogenesis. Therefore, a modified HTS-CLIP method combined with the miR-TRAP technique, which was introduced by Baigude et al (53), will be applied in our future investigations to screen and identify the targets of miR-9 in PC cell lines and the prostate tissue of a PC mouse model. This method may provide a more precise and comprehensive interpretation for the role of miR-9 in PC development.

Acknowledgements
Not applicable.

Funding
This study was supported by a grant from the Shandong Science and Technology Research Program (no. 2014GSF121026).

Availability of data and materials
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions
XJ performed the CCK-8 assay. ZS performed all other assays. LG analyzed the data and wrote the manuscript. GY conceived the study and designed the experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The human specimen experiments were approved by the Ethical Committees of Qilu Hospital of Shandong University (Jinan, China), and written informed consent for sample use was obtained from patients and clinicians. Ethical approval for the animal experiments was provided by the Institutional Animal Care and Use Committee of Shandong University Cancer Center (approval no. LIJ02012016110D).

Patient consent for publication
Written informed consent for sample use and publication in this research was obtained from both patients and clinicians.

Competing interests
The authors declare that they have no competing interests.

References


45. SANG et al: microRNA-9 SUPPRESSES HUMAN PROSTATE CANCER CELLS


